There are thousands of clinical studies in progress for hematologic malignancies, but many are in phase I or II trials, so it may be some time before the most promising compounds add new weapons to the hematology armamentarium, where they are sorely needed.
More than 1 million people suffer from a hematologic malignancy in the United States, and every year another 148,000 men, women, and children are diagnosed with lymphoma, leukemia, or myeloma.
Marshall A. Lichtman, MD
Joseph A. Bertino, MD
|Title||Expiration Date||CME Credits|
|2nd Annual Live Medical Crossfire®: Hematologic Malignancies Online||Sep 28, 2019||8.0|
|Community Practice Connections™: 2nd Annual School of Nursing Oncology™||Sep 28, 2019||1.5|